Maze Therapeutics
MAZE
26.25
-0.18
-0.68%
Maze Therapeutics
US · MAZE
#2998 by market cap
Listed 2025
26.25
-0.18
-0.68%
Live - 5344 symbols - heartbeat 536s ago
· 2026-10-08 04:44
Pre-market
26.25
0.00%
After-hours
26.25
0.00%
- Market cap
- 1.46B
- P/E (TTM)i
- -10.91
- P/Bi
- 3.22
- EPSi
- -2.66
- Div yieldi
- 0.00%
- 52W posi
- 14%
Reader sentiment
Are you bullish or bearish on MAZE?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 18.83, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 4 years
Latest year -100.00% YoY
Margins
Key ratios & quality
- Altman Z-Scorei
- 18.83
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | -- | 0 | 167.50M | 0 |
| Gross profit | -- | -- | -- | -- |
| Selling & admin expenses | 22.83M | 24.61M | 26.42M | 34.45M |
| Research & development | 88.19M | 73.95M | 83.50M | 108.45M |
| Operating profit | -111.03M | -98.55M | 57.59M | -142.90M |
| Pretax profit | -114.94M | -100.42M | 53.40M | -131.12M |
| Tax | -- | 0 | 1.17M | 0 |
| Net profit | -114.94M | -100.42M | 52.23M | -131.12M |
| Basic EPS | -3 | -3 | 0 | -3 |
| Diluted EPS | -3.29 | -2.87 | 0.08 | -3.05 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 20.00M | 0 |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 7.82M | 8.37M | 7.78M | 10.49M | 12.41M | 13.10M |
| Research & development | 27.58M | 28.11M | 25.19M | 27.57M | 34.15M | 34.94M |
| Operating profit | -35.40M | -36.47M | -32.97M | -38.06M | -26.55M | -48.04M |
| Pretax profit | -32.79M | -33.68M | -30.09M | -34.57M | -24.21M | -44.73M |
| Tax | -- | -- | 0 | 0 | -- | -- |
| Net profit | -32.79M | -33.68M | -30.09M | -34.57M | -24.21M | -44.73M |
| Basic EPS | -1 | -1 | -1 | -1 | 0 | -1 |
| Diluted EPS | -1.15 | -0.77 | -0.66 | -0.65 | -0.45 | -0.76 |
Balance sheet
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total current assets | 106.15M | 34.11M | 201.67M | 349.72M |
| Cash & ST investments | 99.92M | 29.16M | 196.81M | 341.92M |
| Inventory | -- | -- | -- | -- |
| Total assets | 149.96M | 71.50M | 240.54M | 397.13M |
| Total current liabilities | 20.78M | 16.32M | 20.67M | 22.56M |
| Short-term debt | 4.32M | 4.49M | 4.63M | 4.80M |
| Long-term debt | -- | 20.08M | -- | -- |
| Total liabilities | 432,416,000.00 | 445,352,000.00 | 551,725,000.00 | 42,161,000.00 |
| Total equity | -282.46M | -373.85M | -311.18M | 354.97M |
| Retained earnings | -295.27M | -395.69M | -358.43M | -489.55M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 299.71M | 271.15M | 391.30M | 349.72M | 379.78M | 420.42M |
| Cash & ST investments | 294.37M | 264.54M | 383.94M | 341.92M | 352.38M | 411.09M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 332.84M | 303.52M | 422.06M | 397.13M | 419.71M | 531.63M |
| Total current liabilities | 18.62M | 19.90M | 22.11M | 22.56M | 21.24M | 22.96M |
| Short-term debt | 4.67M | 4.72M | 4.76M | 4.80M | 4.84M | 4.88M |
| Long-term debt | -- | -- | -- | -- | 38.83M | 38.96M |
| Total liabilities | 40,772,000.00 | 41,281,000.00 | 42,622,000.00 | 42,161,000.00 | 78,009,000.00 | 78,501,000.00 |
| Total equity | 292.07M | 262.24M | 379.44M | 354.97M | 341.70M | 453.12M |
| Retained earnings | -391.21M | -424.89M | -454.98M | -489.55M | -513.76M | -558.48M |
Cash flow
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Operating cash flow | -99.20M | -86.83M | 75.95M | -111.94M |
| Depreciation & amortization | 3.82M | 4.09M | 3.30M | 2.40M |
| Free cash flow | -101.17M | -87.27M | 74.81M | -112.73M |
| Dividends paid | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | 0 | 270.28M |
| Ending cash balance | 101.13M | 30.25M | 197.90M | 190.34M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -29.52M | -30.05M | -24.64M | -27.73M | -39.11M | -15.05M |
| Depreciation & amortization | 684.00K | 649.00K | 571.00K | 499.00K | 444.00K | 391.00K |
| Free cash flow | -29.82M | -30.45M | -24.71M | -27.76M | -39.21M | -15.16M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 127.75M | 3.06M | 139.30M | 163.00K | 0 | 146.66M |
| Ending cash balance | 295.46M | 265.63M | 317.86M | 190.34M | 199.85M | 203.73M |
Returns & efficiency
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| ROE %i | -- | -- | -- | -598.95 |
| ROA %i | -76.65 | -90.68 | 2.18 | -41.12 |
| ROIC %i | -- | -- | -- | -304.96 |
| 5-year avg ROE %i | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | 34.38 | -- |
| FCF / sales %i | -- | -- | 44.66 | -- |
| Current ratioi | 5.11 | 2.09 | 9.76 | 15.50 |
| Quick ratioi | 4.81 | 1.79 | 9.52 | 15.16 |
| Debt / assetsi | 21.38 | 69.40 | 11.07 | 5.87 |
| LT debt / equityi | -- | -- | -- | 5.21 |
| Interest coveragei | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | 0.00 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 1.07 | -- | -213.81 | -598.95 | -38.67 | -37.35 |
| ROA %i | 0.94 | -28.42 | -33.02 | -41.12 | -32.57 | -31.99 |
| ROIC %i | -0.66 | -- | -112.22 | -304.96 | -37.43 | -36.82 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 29.97 | -5,033.20 | -- | -- | -667.28 | -717.86 |
| FCF / sales %i | 41.02 | -- | -- | -- | -- | -- |
| Current ratioi | 16.10 | 13.63 | 17.70 | 15.50 | 17.88 | 18.31 |
| Quick ratioi | 15.81 | 13.29 | 17.36 | 15.16 | 17.54 | 17.90 |
| Debt / assetsi | 7.76 | 8.24 | 5.73 | 5.87 | 14.59 | 11.37 |
| LT debt / equityi | 7.24 | 7.74 | 5.12 | 5.21 | 16.50 | 12.26 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Business of harnessing its understanding of human genetics and variant functionalization to develop100.00%
Quote time 2026-10-08 04:44:40 · For reference only, not investment advice and not tailored to your situation.